Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Expert Panel’s Report Serves as Starting Line for Reform: Asst. Vice Minister
June 30, 2023
-
REGULATORY Japan Mulls Narrowing Down COVID-19 Jabs to Pfizer, but Some Lawmakers Are Skeptical
June 29, 2023
-
BUSINESS Chugai Trims 150 Reps via Voluntary Buyout, Sales Force Down to 1,050 from July
June 29, 2023
-
REGULATORY MHLW Shuffles Senior Bureaucrats, Jo Tapped as Chief of Pharma Bureau
June 28, 2023
-
BUSINESS Amgen Japan to Cut 30 Jobs in Evenity Sales Unit as It Rejigs Organization
June 27, 2023
-
BUSINESS Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023
-
ORGANIZATION FPMAJ Chief Shows Enthusiasm toward Drug Pricing Reform, Vows to Exchange Views with All Affiliate Groups
June 26, 2023
-
ORGANIZATION New JPMA Director General Keen to Make “Special Price Maintenance” Happen after 15 Years
June 23, 2023
-
REGULATORY Chuikyo Kicks Off Debates toward FY2024 Drug Price Reform
June 22, 2023
-
COMMENTARY Honebuto Policy Is Tailwind for Pharma, but Situation Remains Unpredictable
June 22, 2023
-
REGULATORY MHLW to Set Up Separate Forums Focused on Generics and Drug Lags to Execute Expert Panel Proposals
June 21, 2023
-
BUSINESS Wegovy Rollout Being Delayed due to Unprecedented Demand: Novo Japan Chief
June 21, 2023
-
REGULATORY MHLW Study Group to Develop Company Indicators for Generic Supply Systems in FY2023
June 20, 2023
-
REGULATORY MHLW Study Group Proposes Flexibility in Launch Premium Criteria, Broader Comparators
June 20, 2023
-
REGULATORY Japan OKs Honebuto Budget Policy Blueprint, Vows Debates on Longer-Term Drug Costs
June 19, 2023
-
BUSINESS As Wholesalers Try to Negotiate Higher Prices, Hospitals Face Tougher Haggling This Year
June 16, 2023
-
ORGANIZATION Lag and Loss Blamed on Drug Pricing System, JPMA Set to Get Involved in Corrective Steps: President
June 15, 2023
-
BUSINESS AstraZeneca Launches Sales Unit Dedicated to GI Cancer as Imfinzi Expands Label
June 14, 2023
-
REGULATORY LDP Policy Research Council Generally Approves Revised Honebuto Draft
June 14, 2023
-
REGULATORY MHLW Publishes Final Report by Expert Panel on Comprehensive Pharma Policy
June 13, 2023
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…